Predictive Technology Group Integrates Sales and Marketing Team from FlagshipHealth Group 

Move Accelerates Commercialization of Subsidiary Companies’ Products

SALT LAKE CITY, April 23, 2019 — Predictive Technology Group, Inc. (OTC PINK: PRED), a leader in the use of data analytics for disease identification and subsequent clinical intervention through precision therapeutic treatments, announces that it has integrated the sales and marketing team from FlagshipHealth Group, a Predictive consultant contractor. This strategic move is expected to ensure control and growth of sales and marketing efforts for its subsidiary companies, Predictive Biotech and Predictive Laboratories. The integration will enable Predictive and its subsidiaries to combine their domestic direct sales and nationwide distributor network with the sales and marketing team that has joined Predictive from Flagship.

FlagshipHealth Group, a Minneapolis-based provider of strategic sales and consulting services for the healthcare industry, has worked with Predictive Technology Group subsidiary companies to provide guidance and early development of their commercialization strategies. Both Predictive Biotech and Predictive Laboratories have leveraged the collective professional network and relationship capital of FlagshipHealth Group to drive commercial sales, business development and deeper engagement of healthcare stakeholders.

“We are pleased to have the sales and marketing team join the Predictive organization as full-time employees,” said Bradley Robinson, CEO of Predictive Technology Group. “Flagship’s diligence and commitment over the past two years have assisted Predictive in building a strong national sales and distribution team in a short period of time. As we move forward to fully address important challenges, such as clinical trial research for certain indications and reimbursement strategies, we are fortunate to have a team that has demonstrated a tremendous understanding of the complexity and stakeholder diversity of Predictive’s subsidiaries and their markets.”

Michael Herbert, a seasoned marketing professional, has served as Predictive Technology Group’s Executive Vice President since January of 2017. With this integration, Herbert will no longer hold the dual role as Flagship’s Chief Marketing Officer and will focus exclusively on Predictive. In addition to his EVP duties, Hebert will serve as Chief Sales and Marketing Officer for Predictive Biotech on an interim basis.

“We are excited to have Michael join Predictive on a full-time basis, as he brings broad sales and marketing expertise in key areas of healthcare, including human cell and tissue products, molecular diagnostic technologies and patient consumerism,” said Robinson.


About Predictive Technology Group, Inc.
Predictive Technology Group aims to revolutionize patient care through predictive data analytics, novel gene-based diagnostics and companion therapeutics through its subsidiaries Predictive Therapeutics, Predictive Biotech, and Predictive Laboratories. These subsidiaries are focused on endometriosis, scoliosis, degenerative disc disease and human cell and tissue products. The subsidiaries use genetic and other information as cornerstones in the development of new diagnostics that assess a person’s risk of illness and therapeutic products designed to identify, prevent and treat diseases more effectively. Additional information is available at;;; and


Forward-Looking Statements
To the extent any statements made in this release contain information that is not historical, these statements are essentially forward-looking and are subject to risks and uncertainties, including the difficulty of predicting FDA approvals, acceptance and demand for human cell and tissue products and other pharmaceutical products, the impact of competitive products and pricing, new product development and launch, reliance on key strategic alliances, availability of raw materials, availability of additional intellectual property rights, availability of future financing sources, the regulatory environment, and other risks the Company may identify from time to time in the future.



For more information, visit to